Episurf Medical Moving into the US - DNB

Q4 earnings were below our forecast, but there were clear positives in the report including a growing customer base and the first distribution agreement in the US (for the recently cleared patellofemoral implant system). We have made only minor forecast changes and reiterate our fair value of SEK3.3–9.3.

Länk till analysen i sin helhet: https://www.dnb.no/seg-fundamental/fundamentalweb/GetReportSpon.aspx?file=CMPSP_209704.pdf